Xbrane Biopharma Balance Sheet Health
Financial Health criteria checks 2/6
Xbrane Biopharma has a total shareholder equity of SEK171.3M and total debt of SEK175.4M, which brings its debt-to-equity ratio to 102.4%. Its total assets and total liabilities are SEK653.5M and SEK482.2M respectively.
Key information
102.4%
Debt to equity ratio
kr175.40m
Debt
Interest coverage ratio | n/a |
Cash | kr65.40m |
Equity | kr171.34m |
Total liabilities | kr482.17m |
Total assets | kr653.51m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: XBRANS's short term assets (SEK461.7M) exceed its short term liabilities (SEK326.6M).
Long Term Liabilities: XBRANS's short term assets (SEK461.7M) exceed its long term liabilities (SEK155.6M).
Debt to Equity History and Analysis
Debt Level: XBRANS's net debt to equity ratio (64.2%) is considered high.
Reducing Debt: XBRANS's debt to equity ratio has increased from 54.4% to 102.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XBRANS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if XBRANS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.